Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not bearish in the slighest. There is literally no volume so the daily ticks down are not important.
It will all come into fruition with the filing of the first IND. Blue skies after that, and we might see some sunshine with the close of the $20 million and the Fall pot stock craziness, and the looming legalization in California. Not to mention the daily articles of the the booming CBD industry and the public shift to recognizing its medicinal properties.
It will come fast and all at once if you can stomach the fact that, we are in fact the early birds.
They will never do this
If something is PR worthy, they will announce. Like the NB2 data a few weeks ago
PR to fluff The PPS is minor League stuff. Look elsewhere if that is your thing
day to Day is just a Mark
i like where I am sitting on the Racetrack
That is good to hear.
Well, it's a company in research of a plant under schedule 1. To say this is not a difficult play. Is an understatement. GTLA
NEMUS wake up with a PR. This is disgusting. Truly disgusting. Bearish and approaching 52 Week low.
Dr Thomas O'Brien, who has run his own medical marijuana office in New York City for the past year-and-a-half, told Daily Mail Online that he's seen high success rates from his patients dealing with chronic pain.
The type of marijuana he gives to his patients is high in CBD, so he says it doesn't have the psychotic symptoms that critics worry about.
Read more: http://www.dailymail.co.uk/health/article-4789388/Medical-marijuana-does-not-help-chronic-pain-PTSD.html#ixzz4pnc076W5
Follow us: @MailOnline on Twitter | DailyMail on Facebook
Correct, they may have a contingency but it wouldn't make sense to raise now when they've exercised the guaranty.
the advantages
of owning shares of a company
that is not a scam or run by bad operators
Nemus is still committed to Schneider as per the update PR
One would think the funds are coming as they've been putting out news which they couldn't do if they were in the middle of a raise.
10Q
Re Schneider financing
"In connection with the signing of the securities purchase agreement, an affiliate of the purchaser entered into a financial guarantee to the benefit of the Company that provides for payment of the purchase price in full within 90 days of exercise. The Company exercised this guarantee on July 12, 2017."
Yikes. Hope these guys get it together and can pay the 20m.
I remember when I called schneider and asked about what was going on. The guy said 'we still want to do the deal, but we Can't speak for Nemus'. Murphy and Co seemed Pissed off.
I hope management takes their anger out on a NDA submission via 505b2 for NB1222 targeted CINV.
Will need to raise capital first though.
I'm going to slap 50 k more into nemus towards the end of this month hopefully these levels hold!!!!
You didn't per se, but you said "you already know the compounds are efficacious". My point was that cannabinoids aren't going to be effective for every indication, even if the research was validated in an animal model. For example, Sativex failed their cancer pain trial in phase 3, and right now it doesn't look like CBD is effective in treating focal seizures. I wasn't surprised that their trial failed, and you shouldn't be either.
When did I say cannabinoids are a cure all CJ?
Large body of evidence shows cannabis has a variety of therapeutic effects --> those therapeutic effects likely originate from only a few of the 100's of compounds in the plant --> the best way to take advantage of the therapeutic effects of cannabis is to synthetically create and improve the most efficacious compounds for the given indication /thread
Nemus gave Schneider 90 days extension to pay up. 60 days left.
Oh wow, NIH sponsored. For a schedule one drug by the Federal Goverment? Interesting!
Yeah... pharma. is indeed tough. I wait to invest even on phase III. Great human trail results don't always mean the same in real life.
I have been surprised by human studies outside of the phase III tanking a pharma ticker. Pharma. / biotech. is not for the faint of heart.
Nothing yet. Pretty debillitating but it should come through.
Rather comical though to commit to $20 million and not be able to pony up the $$$ when the time comes. Not exactly a small amount of money to agree to.
They had a 90 day extension but one would hope that they dont need the full 90 days. After all Nemus needs the dough!
Waiting on pr of this 20m. Any word yet?
From what I understand, GW is lobbying to have CBD reclassified as a schedule IV drug. In the SD bill, I believe the 'FDA approved only' wording was ultimately removed. I'm not sure about what's happened/happening in other states.
There is an established safety profile, but cannabinoids aren't a cure all.
Looking forward to having a beer together when the market wakes up and we are out of hell. By then VBIO will be at a 4 billion market cap.
NB2 is a CBD analogue
'A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests.'
So maybe that will avoid Any patent infringement issues
NB2111 patent concerns with GW being low energy
It would appear GW is being very Rude about protecting Epidiolex -->
https://hoban.law/blog/2017/2017-02/gw-pharmaceuticals-shot-across-bow-americas-hemp-and-cbd-industries
Thoughts on how this could effect NB2?
Also, did anyone see how GW has delayed completed their NDA for Epidiolex because of construction at a new extraction facility? If only there was a quicker and cheaper way To manufacture....
https://seekingalpha.com/article/4096071-gw-pharmaceuticals-gwph-ceo-justin-gover-q3-2017-results-earnings-call-transcript?part=single
Also, no mention of Sativex during the call. Swing and a Miss
Yes, I understand that
But part of the thesis of cannabinoid drug development is that A. you already know the compounds are efficacious & B. there is already an established safety profile.
I found out that in the ZYN002 trials for PTSD, that patients were not wash the application site of the cream for 12 Hours.
http://zynerba.com/wp-content/uploads/2016/10/ZYN-002-MHSRS-poster-8-9-16v5-1-1.pdf
Someone on Twitter wondered that maybe in the latest trials Zynerba weren't as stringent about the application site post-admin, or weren't allowed to be, compared to their pre-clinical research.
Anyways, congrats to anyone Who caught the ZYNE knife and is riding the wave!
Perhaps the problem is with their permeation enhanced gel. I haven't followed them too closely, but iirc top line data for other indications should be released in the near future.
Not unusual, on average only ~33% of drugs pass phase 2. Even if their research was sound, just because something works in an animal model doesn't mean it will work in a human.
Back when I was making up my mind
how to play Vinpat's thesis, i thought about buying 50/50 NMUS/ZYNE, or all ZYNE and no NMUS.
That was when ZYNE was trading around 20
I don't think it matters whether they succeed or fail with their targets, so I'd rather see them succeed.
I just don't get how something like this would happen. Did they discuss the chance of missing Every metric?
Almost shocking
In their 2016 10-K, it mentions that there is a US patent regarding the treatment of partial seizures with 400mg+ of CBD.
I assume they are referring to this patent from GW.
https://www.google.com/patents/EP2448637A1
Doesn't seem to matter now that the trial for that indication failed. Good reminder about intellectual property protection though.
I haven't looked at it in a couple years but in one of their filings, they disclosed that someone else might contest their patent or patents and they named the individual.
What patent issues?
Unfortunate, but reiterates the importance of risk assessment.
I'd say this news is pretty good. Any time they are presenting data for the superiority of their compounds is a good sign and means the lulls of time are being put to good use.
There's really only two catalysts in the near-term that you (we) are looking for, and thats the close of financing and the filing of the 502(B) for CINV. I think at this point Murphy is trying to be as close to accurate as possible with timelines, in which case that was "3Q or 4Q" for the IND. We're halfway through 3Q, so realistically October is where we should be antsy for the IND.
You're way more knowledgeable on this than I am. I only know what the initial plans were and why they took the paths they've taken. I also know they don't really think that their cannabinoid competitors have anything close to what Nemus has. I know Murphy was right about Zyne. Zyne will also have patent issues if it ever hits.
Listen to this Vinpat guy
Im very lucky to have found him
And to call him a friend
gltfa
Dyodd
Not surprising. The success of their IPO was almost entirely CEO driven. The indications they've targeted are very risky. The Nemus group expected this and these results is one of the reasons why I maintain Nemus has the most valuable IP and have chosen indications with the best likelihood of success.
Zyne got as high as $40 when it first came out. SMH.
This is becoming increasingly painful. Deflated volume, no relevant news... When can we expect some movement here!?!?
https://finance.yahoo.com/news/nemus-bioscience-announces-presentation-cbd-123000241.html
NEMUS Bioscience, Inc. announced that data recently obtained from the company's research and development partner, the University of Mississippi , will be presented at the American Association of Pharmaceutical ...
ZYNE unfortunately came up short in their Phase 2 trial for ZYN002...bad for medical community, hopefully get a boost here.
We've been chattering about how NEMUS science has been better for years from the get-go, so maybe $$$ will flow into here.
THe market could stay irrational
longer than You can stay sane LOL
Good news though; the last PR has been labelled property (NB2111) so we don't have to be confused about this one.
Here is the agenda for the conference: https://cpdaconference.org/wp-content/uploads/2016/05/2017-CONFERENCE-AGENDA-draft-07_28_2017.pdf
If Chico was wondering if it was Fake News
I guess we shouldn't worry about the Financing if they are finding time to present NB2111 research to peers
CANT sure wants to get filled at .253 it seems...
Yes the $20 million will be like,the Big Bang! Tweets, current page. Tweets & replies Media
Nemus Bioscience? @NemusBioscience 4h hours ago
$NMUS Featured in BioWorld for Presentation of NB2111 Analgesic and Anti #Addiction Data at NIH-Sponsored #Cannabinoid Conference https://twitter.com/NemusBioscience
Going to pray every night that this $20 million closes so we can get out of this 10-month deathspiral hellhole.
Incredible that VBIO is valued 6x NEMUS. 6! How long are we gonna have this conversation month after month!??!?!?
They closed a round of $1 mil in financing which is laughable in biotech and they may be literally 18 months behind NEMUS in starting trials.
Delusional market.
Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
The title of the presentation is: "Differential Modulation of Addiction and Pain by Cannabidiol (CBD) and CBD Derivatives."
The data being presented will review the physiology of plant-derived CBD followed by the therapeutic activity associated with the bio-engineered analogue of CBD in multiple animal studies. The proprietary molecule was discovered at the University and Elsohly Laboratories, Inc. (ELI). Findings from the animal studies point to the superiority of the Nemus proprietary analogue of CBD, NB2111, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator. Additionally, NB2111 displayed abuse-deterrent activity in a validated animal model of oxycontin addiction. The in vivo research studying the analgesia and anti-addiction profile of NB2111 was led by Dr. Kenneth Sufka professor of psychology and pharmacology at the University of Mississippi, who will also be presenting data from these studies at the Society of Neuroscience meeting in the fall. https://seekingalpha.com/pr/16904197-nemus-bioscience-announces-presentation-nb2111-analgesic-anti-addiction-data-nih-sponsored
Thank god the market doesnt care at all. For a second I thought this information was pertinent at all in biotech.
I think my local Rite-Aid could raise more interested investors.
News: http://news.sys-con.com/node/4131256
Solid. Love good data.
As discussed on this board before, Murphy is hellbent on broadening the portfolio for increase company and shareholder value. Multiple shots on deck is the name of the game!
Just to be clear, I agree synthetic is the way for to go, which is what Inmed, Zynerba, etc. are also doing. I'm not sure how much of a market share a cannabinoid based antiemetic could capture if it's considered last line, which is why I was curious about vinpat's valuation. Perhaps their buccal patch will change that, when ready.
It will also be interesting to see the efficacy of the current prodrug against a THC suppository. Do you remember seeing a comparison for a previous formulation?
Inferior regarding quality or safety.
I've already explained why it could theoreticaly be a consideration.
I never suggested smoking/edibles were superior.
What study did you reference? No matter, I mentioned IV only because I said transmucosal and transdermal are the most effective methods of delivery, other than IV which would have a 100% bioavailability.
CB1 receptors develop a tolerance to THC fairly quickly, which could affect IOP reduction. It's simply a concern, this is why it's important to account for risk when valuing a drug. We've discussed this - you (I'm paraphrasing) suggested Elsohly et al will figure it out, I thought that was strange and then went to Europe for a few weeks.
I simply asked vinpat whether or not he performed a valuation. If he did I'd be interested in knowing which valuation method and variables he used.
'Plant derived drugs aren't uncommon or inferior.
The advantage with biosynthesis is mainly reduced time and cost.'
If one route of manufacturing produces a higher volume with less costs, how is the other method not inferior? I know it is not uncommon, but wouldn't cannabis variability make it more difficult than your average plant? The more variable the species = the more synthetics make the better route? Why are you even bothering Growing it considering the risks and GMP costs....
Targeted synthetics outperform the plant 10/10 times for that specific indication. Even if some of the 550ish compounds have a net positive effect, clearly it is not big enough to warrant smoking/edibles over a synthetic. And if they do have a benefit, that will be discovered and drugs improved one day.
Are cannabinoids via IV the best? The study I referenced would indicate not.....
'hough I'm skeptical that NB1111 will be successful because of tolerance'
Tolerance to what? The latest research said 1%< THC?
'"But if it's valued at a couple hundred million $$ then that's not bad for a few years work...".
Not bad at all, is that just a hypothetical figure or what you actually think it could be worth to Nemus? '
If the CINV market is 2b, and they can get 5% of that for a sustained period, you can do the math
Plant derived drugs aren't uncommon or inferior. The advantage with biosynthesis is mainly reduced time and cost. There could be indications where the whole plant may be superior to THC alone, perhaps where CBD could moderate the psychoactive effect of THC, if the dose were high enough. Other cannabinoids could have a synergistic effect as well, possibly even terpenes though it would take years to study. Some researchers are skeptical of the entourage effect, it would be interesting to study dronabinol against a bioequivalent edible rather than inhaling cannabis (if it hasn't already been done).
The delivery method is critical, transmucosal/transdermal are unquestionably the most effective, other than intravenous. A topical preparation would of course be most effective for glaucoma (though I'm skeptical that NB1111 will be successful because of tolerance).
"But if it's valued at a couple hundred million $$ then that's not bad for a few years work...".
Not bad at all, is that just a hypothetical figure or what you actually think it could be worth to Nemus?
Followers
|
138
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6315
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |